Baseline characteristics of studied patient population (n = 1295)
| Characteristic . | n (%) . |
|---|---|
| Sex, n (%) | ♀ 744 (57) |
| ♂ 555 (43) | |
| Age, y | Range: 47-75 |
| MPN, n (%) | |
| Essential thrombocythemia | 700 (54) |
| Polycythemia vera | 473 (37) |
| Primary myelofibrosis | 103 (8) |
| Unclassified | 19 (1) |
| Mutational status,*n/N (%) | |
| JAK2+ | 485/550 (88) |
| CALR | 24/190 (13) |
| MPL | 7/196 (4) |
| JAK2ex12 | 1/31 (3) |
| Triple− | 9/131 (7) |
| Prior thrombosis, n (%) | |
| Arterial thrombosis | 383 (30) |
| Venous thrombosis | 738 (57) |
| DVT/PE | 278 (38) |
| Splanchnic vein thrombosis | 286 (39) |
| Cerebral (sino)venous thrombosis | 8 (1) |
| Not specified | 162 (22) |
| Both arterial and venous thrombosis | 8 (0.6) |
| Characteristic . | n (%) . |
|---|---|
| Sex, n (%) | ♀ 744 (57) |
| ♂ 555 (43) | |
| Age, y | Range: 47-75 |
| MPN, n (%) | |
| Essential thrombocythemia | 700 (54) |
| Polycythemia vera | 473 (37) |
| Primary myelofibrosis | 103 (8) |
| Unclassified | 19 (1) |
| Mutational status,*n/N (%) | |
| JAK2+ | 485/550 (88) |
| CALR | 24/190 (13) |
| MPL | 7/196 (4) |
| JAK2ex12 | 1/31 (3) |
| Triple− | 9/131 (7) |
| Prior thrombosis, n (%) | |
| Arterial thrombosis | 383 (30) |
| Venous thrombosis | 738 (57) |
| DVT/PE | 278 (38) |
| Splanchnic vein thrombosis | 286 (39) |
| Cerebral (sino)venous thrombosis | 8 (1) |
| Not specified | 162 (22) |
| Both arterial and venous thrombosis | 8 (0.6) |
Proportion of patients in whom MPN mutational status was assessed.
CALR, calreticulin gene mutation; DVT, deep vein thrombosis; JAK2, janus kinase 2 (V617F) mutation; JAKex12, janus kinase 2 exon 12 mutation; MPL, myeloproliferative leukemia virus oncogene mutation.